Clinical trials: Heart Failure NYHA Class III
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure and Reduced Ejection Fraction, NYHA Class III Heart Failure
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
The purpose of this prospective, multi-center, propensity-matched coverage with evidence development (CED) study is to assess the impact of cardiac contractility modulation (CCM) on mortality and heart failure hospitalizations in…
- Trial name
- BRIGHTEN-HF (NCT07209098)
- Testing
- Cardiac Contractility Modulation (CCM)
- Where
- United States
- Volunteers
- 4,200 people
- Sponsor
- Impulse Dynamics
Heart Failure
Optimal Balance Alfapump® System Feasibility Study
1. Summary of Clinical Investigation A summary of the clinical investigation is provided below and includes the primary objective of the study, the safety and feasibility endpoints, the number of subjects to be enrolled, the…
- Trial name
- OPTIMALBALANCE (NCT03032211)
- Testing
- Alfapump
- Where
- Hungary
- Sponsor
- Sequana Medical N.V.
Heart Failure NYHA Class II, Heart Failure NYHA Class III
CardioMEMS HF System Real-World Evidence Post-Approval Study
The purpose of this post-approval study (PAS) is to evaluate the long-term safety and effectiveness of the CardioMEMS™ HF System using real-world evidence (RWE) methods.
- Trial name
- NCT06306573
- Testing
- CardioMEMS HF System
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Heart Failure NYHA Class III
HEart fAiluRe evaluaTion Questionnaire
The "four-point" questionnaire by Severo and his associates was weighted in 2011 in the Portuguese population and aims to characterize the severity of the symptoms of heart failure by providing a way to minimize the reliability…
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure NYHA Class II, Heart Failure NYHA Class I
- Trial name
- HEART (NCT03895073)
- Testing
- healthy volunteers
- Where
- Greece
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- John Parissis
Congestive Cardiac Failure
Renal Artery Denervation in Chronic Heart Failure
Heart failure is a common condition with debilitating symptoms and a poor prognosis. Patients with heart failure have a massively overactive sympathetic nervous system which attempts to compensate for their poorly functioning…
- Trial name
- REACH-Pilot (NCT01584700)
- Testing
- Renal Artery Denervation
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
Congestive Heart Failure(CHF)
Ketone and Hawthorn Extract Supplementation in Congestive Heart Failure
The purpose of this research is to gain a better understanding of whether supplements can improve heart health. There are a number of study procedures and tests that will occur as a part of the research study.
- Trial name
- NCT07166965
- Testing
- Hawthorn supplement, Ketones
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Jefferson University
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Optimization of STAR
The aim of this study is optimize the STAR (SympTom mAnagement self-caRe) intervention to support patients with HF in staying healthy, and particularly in self-monitoring and managing symptoms.
- Trial name
- STAR (NCT07065578)
- Testing
- STAR condition 1, STAR condition 2, STAR condition 3
- Volunteers
- 320 people
- Sponsor
- UMC Utrecht